CoChat

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?

Open access
Mosterd, Charlotte M., Bjornstad, Petter, van Raalte, Daniël H. · 2020 · Journal of Nephrology

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D). These drugs have potent glucose-lowering actions and, additionally, lower body weight through satiety induction while reducing blood pressure and dyslipidemia. Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof. In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need. In this review we will discuss the evidence which suggests renoprotection induced by GLP-1 receptor agonists and the potential mechanisms that may be involved. These include mitigation of hyperglycemia, overweight and insulin resistance, systemic and glomerular hypertension, dyslipidemia, sodium retention, inflammation and renal hypoxia. The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40620-020-00738-9

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GLP-1 receptor agonists effects on established and presumed drivers of diabetic kidney disease (DKD). In blue boxes, established renal risk factors that are mitigated by GLP-1 receptor agonism (illustrated by a red cross). The risk factors of sodium retention and glomerular hyperfiltration (green boxes) are likely not reduced by GLP-1 receptor agonists. Finally, in yellow boxes, more recently discovered mechanisms of renal damage including inflammation and renal hypoxia are indicated. It is unclear whether GLP-1 receptor agonism modulates these pathways (color figure online)
Fig. 1 GLP-1 receptor agonists effects on established and presumed drivers of diabetic kidney disease (DKD). In blue boxes, established renal risk factors that are mitigated by GLP-1 receptor agonism (illustrated by a red cross). The risk factors of sodium retention and glomerular hyperfiltration (green boxes) are likely not reduced by GLP-1 receptor agonists. Finally, in yellow boxes, more recently discovered mechanisms of renal damage including inflammation and renal hypoxia are indicated. It is unclear whether GLP-1 receptor agonism modulates these pathways (color figure online)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 57

Metadata

Authors
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • University of Colorado Anschutz (US)
Venue
Journal of Nephrology
Published
2020-04-30
Volume
33
Issue
5
Pages
965-975
ISSN
  • 1121-8428 (ISSN-L)
  • 1724-6059
OpenAlex
W3023544430
Cited by
56
References
67
Citations by year
2026: 8 · 2025: 7 · 2024: 12 · 2023: 8 · 2022: 11 · 2021: 7 · 2020: 3
FWCI
1.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nephrology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
GLP-1 receptor agonists, diabetic nephropathy, renal protection, semaglutide, type 2 diabetes, albuminuria, hyperglycemia, insulin resistance, glomerular hypertension, dyslipidemia, sodium retention, renal inflammation, renal hypoxia, FLOW trial
MeSH terms
Glucagon-Like Peptide-1 Receptor, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Pharmaceutical Preparations, Humans, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nephroprotective effects of GLP-1 receptor agonists: where do we stand? https://app.cochat.ai/papers/10.1007/s40620-020-00738-9
The paper
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020). Nephroprotective effects of GLP-1 receptor agonists: where do we stand? Journal of Nephrology. https://doi.org/10.1007/s40620-020-00738-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.